Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310456 | 0.84 | SMN1; SMN2 (0.60) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL2397410 | 0.81 | GRIN2B (0.49) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL5742351 | 0.80 | MAPT (0.58) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL2494773 | 0.78 | DHFR (0.59) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL2514320 | 0.74 | DRD2 (0.50) | KDM4ELMNADGAT1 | |
| SCHEMBL31557722 | 0.74 | OPRL1 (0.62) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL14503590 | 0.74 | OPRL1 (0.58) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL10079145 | 0.73 | OPRL1 (0.64) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL30227020 | 0.71 | OPRL1 (0.59) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 | |
| SCHEMBL26706222 | 0.71 | OPRL1 (0.59) | MAPTSMN1; SMN2NPC1RAB9AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | claimed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2378878-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT2, DGAT1, ACAT2 | MAPT 3731/4885SMN1; SMN2 4770/4885NPC1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.